SLU-PP-332
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.
Mechanism of Action
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.
Key Benefits
- Exercise mimetic effects without physical activity
- 12% weight loss in 28 days
- 70% increased endurance
- 25% enhanced fatty acid oxidation
- Improved insulin sensitivity
- Reduced hepatic steatosis
- Cardiac protection
- Reversal of age-related mitochondrial dysfunction
(E)-4-Hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide Complex or non-standard sequence format
Metabolic Health
- Weight Loss & Body Composition
12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.
- Insulin Sensitivity & Glucose Control
Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.
- Energy Expenditure Enhancement
Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.
- Liver Health & NAFLD
Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.
Exercise Performance
- Endurance Improvements
70% increase in running time and 45% increase in running distance in preclinical models.
- Muscle Fiber Remodeling
Increased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.
Cardiovascular
- Cardiac Function Improvement
Improved ejection fraction in heart failure models with reduced cardiac fibrosis.
Anti-Aging
- Mitochondrial Aging Reversal
First compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.
Kidney Protection
- Age-Related Kidney Disease
Reversed age-related albuminuria increase and prevented podocyte loss in elderly mice.
Research compound - IP injection in animals only. No human administration protocols established.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard Metabolic Protocol | 50 mg/kg (animal dosing) | Twice daily | Intraperitoneal injection (IP) |
| Acute Exercise Enhancement | 50 mg/kg (animal dosing) | Single dose 1 hour pre-exercise | Intraperitoneal injection (IP) |
| Extended Treatment | 50 mg/kg (animal dosing) | Twice daily for 4-8 weeks | Intraperitoneal injection (IP) |
Reconstitution Instructions
- Bacteriostatic water (BAC) required
- Sterile technique essential
- 1 WARNING: Not tested in humans - research only
- 2 Do NOT use outside approved research protocols
- 3 Dosing cannot be extrapolated from animals to humans
- 4 No human clinical trials initiated as of 2025
- 5 Oral formulation in development
- 6 Consult medical professionals before experimental use
Both affect mitochondrial function and AMPK pathways - may have additive metabolic effects. Monitor blood glucose closely.
Enhanced insulin sensitivity may require significant dose reduction to prevent hypoglycemia.
Different mechanisms affecting weight loss and metabolism - combination could have additive effects.
Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.
Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.
Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.
GH optimization may complement metabolic enhancement for body composition without known interactions.
May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.
Metabolic shift toward fat oxidation within 2 hours; gene expression changes at 3-6 hours; enhanced exercise performance 1 hour post-dose
Increased resting energy expenditure measurable; enhanced fatty acid oxidation by 25%; improved grip strength by day 6
Up to 12% weight loss by day 28; dramatic fat mass reduction; improved glucose tolerance; 45-70% endurance improvements; reduced hepatic steatosis
Cardiac improvements (ejection fraction, reduced fibrosis); age-related kidney dysfunction reversal; mitochondrial architecture restoration
Sustained anti-aging effects in aging studies; continued tissue mitochondrial improvement; duration after discontinuation unknown
Common Side Effects
- Animal studies show favorable safety with no severe effects at therapeutic doses
- Well-tolerated in rodents and canines
- No liver, kidney, or cardiac toxicity documented
- No lean mass loss
- Does not suppress hormones or act as stimulant
- Minor plasma cholesterol and liver enzyme changes in some studies
Stop Signs - Discontinue if:
- Severe hypoglycemia (especially with diabetes medications)
- Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)
- Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)
- Kidney problems (reduced urination, swelling, severe back pain)
- Severe headaches or neurological symptoms
- Allergic reactions (rash, hives, difficulty breathing, swelling)
Contraindications
- NOT FOR HUMAN USE - no approved human dose
- No human clinical trials conducted
- Potential interaction with diabetes medications
Good Signs
- Legitimate research supplier with Certificate of Analysis
- From reputable chemical suppliers (Cayman Chemical, Sigma-Aldrich)
- Proper labeling as 'Research Use Only'
- Batch numbers and purity data (typically >98%)
Warning Signs
- Research chemical only - NOT FOR HUMAN USE
- NOT FDA approved - no human clinical trials
- Available only for legitimate research through licensed suppliers
Bad Signs
- Any product marketed for human consumption is illegal
- Unknown purity or contamination without lab testing
- Lack of proper HPLC or mass spectrometry verification
- Products without 'Research Use Only' labeling
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome(2024)
Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis.
- Synthetic ERRα/β/γ Agonist Induces Acute Aerobic Exercise Response(2023)
Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers.
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction in Aging Kidney(2023)
21-month-old mice, 8-week treatment: Reversed age-related kidney decline, reduced albuminuria, prevented podocyte loss, restored mitochondrial architecture.
- Cardiac Protective Effects of Pan-ERR Agonists(2021)
Heart failure models, 6-week treatment: Improved ejection fraction, ameliorated cardiac fibrosis, improved survival, enhanced mitochondrial ultrastructure.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.